Following an application from Danone France, submitted pursuant to Article 14(1)(a) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Danacol® on blood cholesterol (Question No EFSA-Q-2008-779) [The EFSA Journal (2009) 1177, 1-12.]. The claim proposed by the applicant was worded as follows: ‘Danacol® reduces LDL-cholesterol by 10 % in 3 weeks, and the reduction is maintained with daily consumption. High blood cholesterol is one of the main risk factors in the development of (coronary) heart disease’.
Recital 6, Commission Regulation (EU) No 384/2010 of 5 May 2010 on the authorisation and refusal of…
In forcesince 5 May 2010